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Abstract Previously, we developed a 3-dimensional cell culture model of human tuberculosis
(TB) and demonstrated its potential to interrogate the host-pathogen interaction (Tezera et al.,
2017a). Here, we use the model to investigate mechanisms whereby immune checkpoint therapy
for cancer paradoxically activates TB infection. In patients, PD-1 is expressed in Mycobacterium
tuberculosis (Mtb)-infected lung tissue but is absent in areas of immunopathology. In the
microsphere model, PD-1 ligands are up-regulated by infection, and the PD-1/PD-L1 axis is further
induced by hypoxia. Inhibition of PD-1 signalling increases Mtb growth, and augments cytokine
secretion. TNF-a is responsible for accelerated Mtb growth, and TNF-a neutralisation reverses
augmented Mtb growth caused by anti-PD-1 treatment. In human TB, pulmonary TNF-a
immunoreactivity is increased and circulating PD-1 expression negatively correlates with sputum
TNF-a concentrations. Together, our findings demonstrate that PD-1 regulates the immune
response in TB, and inhibition of PD-1 accelerates Mtb growth via excessive TNF-a secretion.
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Introduction
Tuberculosis (TB) continues to be a global health pandemic, killing more people than any other
infection (Wallis et al., 2016). TB involves a complex host-pathogen interaction, with humans and
Mycobacterium tuberculosis (Mtb) having undergone prolonged co-evolution (Menardo et al.,
2019). TB has often been thought to primarily result from loss of immune control, because approxi-
mately 90% individuals infected with TB never progress to active disease, and this progression is
increased in the context of immune deficiency; such as in cases of HIV infection, in infants, people
with genetic deficiency of the IL-12/IFN-g signalling pathway or after anti-TNF-a antibody treatment
(O’Garra et al., 2013). However, an emerging concept is that an excessive immune response to Mtb
may be equally harmful. Standard disease paradigms predict that immune activation resulting from
the administration of checkpoint inhibitors should lead to better control of Mtb infection
(Zumla et al., 2016). However, counter-intuitively these agents seem to be activating TB, as evi-
denced by recent reports of TB developing in patients treated for malignancy with immune check-
point inhibition, often rapidly after commencing therapy (Fujita et al., 2016; Lee et al., 2016;
Chu et al., 2017; Picchi et al., 2018; Jensen et al., 2018; Elkington et al., 2018; He et al., 2018;
Takata et al., 2019; Barber et al., 2019; Tsai et al., 2019; van Eeden et al., 2019). Consistent with
this emerging clinical phenomenon, programmed death (PD-1) deficient mice are highly susceptible
to TB, dying more rapidly than T-cell deficient mice (La´za´r-Molna´r et al., 2010; Barber et al.,
2011).
PD-1 and its ligand PD-L1 are expressed in human granulomas (Elkington et al., 2018), suggest-
ing a regulatory role at the site of disease. TB granulomas are hypoxic (Belton et al., 2016), and PD-
L1 is up-regulated by hypoxia (Noman et al., 2014), further suggesting a mechanistic link between
hypoxia and the PD-1/PD-L1 axis within TB lesions. In this study, we investigate the expression pat-
terns of PD-1 and PDL-1 within TB infected human lung tissue and the relationship between PD-1
and anti-TB immunity. Next, using a human 3D cell culture model of TB (Tezera et al., 2017a), we
show that hypoxia increases expression of PD-1 and its ligands, that PD-1 inhibition increases Mtb
growth. Surprisingly, TNF-a is primarily responsible for this effect, and TNF-a neutralisation reverses
the anti-PD-1 induced phenotype.
Results
PD-1 is expressed in human TB granulomas but not in areas of
immunopathology
First, we investigated the presence and localisation of PD-1-expressing T cells in human pulmonary
TB. We hypothesised that PD-1 would be expressed by T cells in the lung of patients with TB, and at
a higher frequency than in the blood. In thirty-five patients undergoing medically indicated lung
resection to treat TB or TB sequalae, PD-1 expression was measured on T cells isolated from the
lung and matched blood samples, available for 23 patients, by flow cytometry. Overall, PD-1 expres-
sion in homogenized lung tissue was highly variable, with a trend towards increased PD-1 in both
CD4 and CD8 T-cells from the lung compared to matched blood, which reached statistical signifi-
cance for CD8 T-cells (Figure 1A). Lung tissue from healthy individuals was not available for study,
however, the median frequency of 11% and 14% of PD-1+ CD4 and CD8 T-cells observed are gener-
ally lower than recently reported for healthy human lung tissue from organ donors of approximately
50% for both cell types (Snyder et al., 2019). As lung tissue is highly perfused with blood, distin-
guishing cells of lung or blood origin is challenging.
To explore this further, we stained lung samples for canonical markers of tissue resident T-cells,
CD69 and CD103 (Snyder et al., 2019). PD-1 expression on lung CD4 cells was predominantly
restricted CD69+ T-cells, with a smaller proportion also expressing CD103 (Figure 1B, overall fre-
quencies Supplementary file 1), consistent with a tissue resident phenotype and in contrast to PD-1
expressing cells in blood, which are largely CD69 negative (Figure 1—figure supplement 1). Lung
CD8 T-cells were also found to predominantly express CD69 in addition to CD103, again in contrast
to CD8 T-cells in circulation. Therefore, these data are consistent with expression of PD-1 on lung
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Figure 1. PD-1 is expressed in human TB granulomas. (A) Analysis of PD-1 expression by T cells in the lung and peripheral circulation of thirty-five TB
patients undergoing medically indicated lung resection. PD-1 shows a trend towards higher expression by lung CD4+ (i) and is significantly higher on
lung CD8+ (ii) T cells. Significance analysed by one-tailed unpaired Mann-Whitney test. (B) Flow cytometric analysis of lung parenchyma CD4+ (i) and
CD8+ (ii) T cells from TB patients based on the expression of PD-1, CD69 and CD103 demonstrates increased PD-1 expression in the resident T cells in
the lung parenchymal cells. Significance analysed by Kruskal-Wallis test with Dunn’s multiple comparison test. (C) Immunohistochemical staining for PD-
1+, CD4+ and CD8+ expression in human lung TB granulomas. PD-1 is expressed around the central macrophage core in the same region as CD4+ (ii)
and CD8+ (iii) T cells. Co-localization of PD-1 (blue), CD4+ (red) and CD8+ (yellow) using false colour of the immunostaining shows co-localisation of PD-
1 with both CD4+ and CD8+ cells (purple and green respectively) (iv). Scale bar 100 mm. (D) PD-1 is not expressed in caseating granulomas where
immunopathology is present in human lung biopsies (i). Six biopsies taken as part of routine clinical care were studied. CD4+ (ii) and CD8+ (iii)
expressing cells are present in the same area, and so absence of PD-1 immunoreactivity is not due to lack of viable cells. Scale bar 200 mm.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. PD-1 expression on peripheral CD4+ and CD8+ T-cells is predominantly on CD103- and CD69-negative cells.
Figure supplement 2. PD-1 expressing cells are absent in the immediate region surrounding caseous necrosis in human TB granulomas.
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tissue resident T-cells in patients with active or previous pulmonary TB infection. However, TB immu-
nopathology is highly heterogenous within the lung and these analyses do not provide information
as to the localization of PD-1 expression within TB lesions.
To address this question, we performed immunohistochemical analysis of human lung biopsies of
patients with active TB. Within stable granulomas with an intact cellular structure, PD-1 expression
was present around the central macrophage core (Figure 1C–i). Both CD4 and CD8 T cells were
present in the granuloma (Figure 1C–ii and -iii), and co-localisation analysis demonstrated that a
proportion of both T cell subtypes expressed PD-1 (Figure 1C-iv), consistent with the flow cytometry
data. In contrast, in caseating granulomas with evident immunopathology, PD-1 expression was
totally absent (Figure 1D–i and Figure 1—figure supplement 2). The lack of immunoreactivity was
not due to lack of viable cells, as CD4 and CD8 expressing T cells were present within the same area
(Figure 1D–ii and -iii). Therefore, in human granulomas, PD-1 is expressed in areas where the host-
pathogen interaction appears stable but is absent in regions of immunopathology.
The PD-1/PD-L1 axis is up-regulated in the 3D microsphere model
Taken together, these data from Mtb infected patients demonstrate that PD-1 is expressed by lung
resident T-cells and may be required to prevent destructive lung disease. However, whether this is a
causal associated remains unclear. We therefore explored the biological role of PD-1 expression in a
3-dimensional (3D) human tissue culture model. TB is a human disease characterised by a prolonged
host-pathogen interaction in 3D, and is regulated by the extracellular matrix, and previously we have
previously developed a 3D cell culture model incorporating extracellular matrix to investigate TB
pathogenesis (Tezera et al., 2017a; Tezera et al., 2017b). Here, we first studied migration of cells
within the alginate-collagen matrix by performing time-lapse microscopy (Figure 2A and Video 1).
For this experiment only, UV killed Mtb was used to permit the imaging outside the containment
level three laboratory. From 24 hr, progressive accumulation occurs around a central infected core,
resulting in a large multicellular granuloma by 48 hr with dynamic cellular movement similar to the T
cell mobility observed in mouse BCG granulomas (Egen et al., 2008).
We next investigated whether the PD-1/PD-L1 axis was up-regulated by infection in this 3D
model, and found that Mtb infection increased PD-L1 and PD-L2 gene expression at 4 days post
infection (Figure 2B). Furthermore, a hypoxic environment (1% oxygen) further increased PD-L2
expression. PD-1 gene expression was not increased at 72 hr by Mtb infection under normoxic con-
ditions, but was up-regulated when infected cells were incubated in hypoxia (Figure 2B). The change
in expression required both infection and hypoxia, as hypoxia did not increase PD-1 or PD-L1/2
expression alone (Figure 2—figure supplement 1). We then studied PD-1/PD-L1 cellular surface
expression in microspheres by flow cytometry after one week of infection. Mtb infection slightly
increased PD-1 surface expression on CD4+ T cells in normoxia, which was augmented by hypoxia
(Figure 2C). Similarly, Mtb infection increased PD-1 expression on CD8+ T cells, which was greater
in hypoxia (Figure 2D). Furthermore, on CD14+ CD11b+ cells, PD-L1 expression was increased by
infection and more so in hypoxia (Figure 2E). To investigate whether the effect of hypoxia on
increased PD-1/PD-L1 expression was due to altered Mtb growth, we studied proliferation using
Mtb expressing firefly luciferase and also colony counting on Middlebrook 7H11 agar. Hypoxia inhib-
ited Mtb growth by both readouts (Figure 2F and Figure 2—figure supplement 2A). As expected,
hypoxia also increased expression of the hypoxia inducible factor, HIF-1a, in host cells (Figure 2G),
but did not have a significant effect on host cell survival (Figure 2—figure supplement 2B). There-
fore, the increased PD-1 and PD-L1/2 expression in hypoxia was not due to increased Mtb growth or
a change in host cell viability.
PD-1 pathway inhibition increases Mtb growth in the 3D model
Having demonstrated that the PD-1/PD-L1 axis was up-regulated by infection in the 3D model, we
investigated whether inhibition of this interaction modulated host control of Mtb. We initially studied
chemical inhibitors of the PD-1/PD-L1 axis (Inhibitor 1, C29H33NO5) and found that blocking PD-1/
PD-L1 binding increased Mtb growth in a dose-dependent manner (Figure 3A). This effect occurred
in both normoxia and hypoxia (Figure 3—figure supplement 1). No effect of PD-1 inhibition on cell
survival was noted at day 7 or day 14, utilising two different assays suited to each time point
(Figure 3B and C). Next, we studied spartalizumab, a humanised monoclonal antibody with high-
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Figure 2. The PD-1/PD-L1 axis is upregulated in the 3D TB granuloma system. (A) Still images from time-lapse microscopy imaging demonstrating
increasing cellular aggregation of PBMC around a focus of ultraviolet killed Mtb H37Rv in the 3D granuloma system at times 0, 12, 24 and 48 hr post
encapsulation in the matrix. The Z projection shows the cells contained within the designated volume in a 2D reconstruction. Full time course in
Video 1. (B) Gene expression of PD-1 and its ligands in the 3D microsphere model. RNA was extracted from live Mtb-infected PBMC and relative
Figure 2 continued on next page
Tezera et al. eLife 2020;9:e52668. DOI: https://doi.org/10.7554/eLife.52668 5 of 23
Research advance Immunology and Inflammation
affinity to PD-1 that blocks the interaction with PD-L1 and PD-L2 (Kaplon and Reichert, 2019). Con-
sistent with the chemical inhibition, PD-1 pathway inhibition using spartalizumab increased Mtb
growth in normoxia in a dose-dependent manner (Figure 3D). Similarly, in hypoxia spartalizumab
increased Mtb growth (Figure 3E). Microspheres must be restored to normoxia to measure Mtb
luminescence, and therefore a single time point was analysed. Anti-PD-1 antibody treatment had no
significant effect on cell survival in either normoxia or hypoxia (Figure 3F).
PD-1 inhibition increases secretion of multiple cytokines and growth
factors
To investigate the underlying mechanism whereby PD-1 inhibition leads to increased Mtb growth,
we studied secretion of cytokines, chemokines and growth factors by measuring accumulation in the
media around Mtb-infected microspheres by Luminex array. Mtb infection increased secretion of
numerous analytes (Figure 4—figure supplement 1), and inhibition of PD-1/PD-L1 signalling further
significantly augmented secretion of twelve analytes compared to Mtb infection alone (Figure 4). A
similar augmentation of analyte secretion was observed in hypoxic microspheres (Figure 4—figure
supplement 2). The twelve analytes that were further increased above Mtb infection with concurrent
PD-1 inhibition were IL-4, IL-6, IL-10, IL-12, TNF-a, IL-1RA, MIP-1a, MIP-1b, RANTES, G-CSF, GM-
CSF and VEGF (individual concentrations, Fig-
ure 4—figure supplement 1). Anti-PD-1 alone
increased TNF-a secretion, although to a lesser
effect than in combination with Mtb infection
(Figure 4—figure supplement 3).
Exogenous TNF-a increases Mtb
growth in microspheres
To establish which of these factors might be
associated with increased Mtb growth, we
added the significantly upregulated analytes
either individually or in combination pools to 3D
microspheres in normoxia at ‘low’ (Figure 5) and
‘high’ concentrations (Figure 5—figure supple-
ment 1), as determined by the concentration
measured in the secretion analysis. TNF-a was
the dominant cytokine that increased Mtb
growth, with other cytokines only having a minor
effect (Figure 5A). Chemokines (RANTES, MIP-
1a and MIP-1b) and growth factors (G-CSF) had
no significant effect, while GM-CSF significantly
Figure 2 continued
expression investigated by qRT-PCR at day four post infection. Open bars, normoxia, filled bars 1% hypoxia. PD-L1 and PD-L2 are upregulated by Mtb
infection, and in 1% hypoxia PD-1 expression is increased and PD-L2 expression further augmented (n = 4). Results are normalised against the
housekeeping genes GAPDH, b-Microbulin and FANTA and showed similar results. b-microglobulin used for (B). *p<0.05, **p<0.01. (C–E) Surface
expression of PD-1 and PD-L1. PBMCs were decapsulated from Mtb-infected microspheres at day seven and surface expression of PD-1 and its ligand
PD-L1 were analysed by flow cytometry. PD-1 is expressed in CD4+ (C) and CD8+(D) T cells in PBMC from Mtb infected microspheres incubated in
normoxia. PD-1 expression was significantly upregulated in 1% hypoxia. Representative flow cytometry plots and level of expression of PD-1 by the
CD4+ and CD8+ T cell fractions are shown (n = 4). (E) PD-L1 expression on CD14+CD11b+ cells within PBMC in Mtb infected microspheres is
upregulated in both normoxia and 1% hypoxia at day 7 (n = 4). Significance of *p<0.05. (F) Growth of Mtb H37Rv ffLux+ in microspheres in normoxia
and 1% hypoxia measured at day 3, 7 and 14. Hypoxia reduces Mtb growth. (G) Hypoxia inducible factor 1a (HIF-1a) mRNA levels were increased in
Mtb-infected microspheres incubated in 1% hypoxia. RNA was extracted from decapsulated microspheres and normalised to uninfected microspheres
in the same environment. Results were normalised to the housekeeping genes GAPDH, b-microglobulin and FANTA to check the housekeeping gene
are not affected by hypoxia. Similar results all three of the housekeeping genes. b-microglobulin used for this graph. Significance ***p<0.001.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Hypoxia alone has no significant effect on expression of the PD-1/PD-L1/2 axis.
Figure supplement 2. Mtb growth is reduced in hypoxia, while host cell viability is unchanged.
Video 1. Cell migration over 48 hr around a central
cluster of macrophages infected with UV-killed Mtb
within a 3D alginate-collagen matrix. Migration is seen
in the first 24 hr, without aggregation, and then
progressive granuloma formation occurs.
https://elifesciences.org/articles/52668#video1
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increasing Mtb growth, but the effect was smaller than for TNF-a (Figure 5B). Additionally, the only
cytokine combination that had a significant effect on Mtb growth was the pro-inflammatory pool
containing TNF-a, IL-6 and IL-12 (Figure 5C). The addition of Th2 cytokines, chemokines or other
growth factors had no significant effect (individual growth curves at ‘high’ concentration, Figure 5—
figure supplement 1). Furthermore, TNF-a had a progressive dose-dependent effect increasing
Mtb growth within microspheres (Figure 5D).
To explore the effect of TNF-a further, we then generated microspheres incorporating infected
PBMC with and without anti-TNF-a neutralising antibodies. Consistent with our initial observation,
anti-TNF-a neutralising antibodies suppressed the TNF-mediated increased Mtb growth, with a par-
tial reduction at each concentration studied of two different neutralising antibodies (Figure 5E and
Figure 5—figure supplement 2). Exogenous TNF-a modulated macrophage polarisation within
microspheres, reducing CD80 expression at day 7 (Figure 5—figure supplement 3). Therefore, we
next investigated whether anti-PD-1-induced Mtb growth could be reversed by blocking TNF-a
activity. Anti-PD-1 antibody treatment of infected cells again augmented Mtb growth, and this
increased growth could be reversed by the incorporation of anti-TNF-a antibodies into the
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Figure 3. PD-1 pathway inhibition increases Mtb growth. (A) Inhibition of PD-1 receptors by small chemical inhibitor one increases Mtb growth in a
dose-response manner (1–1000 nM). Inhibitor concentration 1 nM (green), 10 nM (purple), 100 nM (blue) and 1 mM (red). (B) Inhibitor one was not toxic
to Mtb-infected PBMC, analysed by CytoTox-Glo assay (Day 7). (C) Cellular toxicity was no different at day 14 as analysed by LDH release.
Concentration 1 and 1000 nM were analysed for toxicity. (D) Spartalizumab, a therapeutic monoclonal anti-PD-1 antibody, progressively increased Mtb
growth in microspheres in normoxia in a dose-dependent manner. (E) Spartalizumab also increased Mtb growth in hypoxia. Media (black), isotype
(blue), spartalizumab 20 mg/ml (green) and 200 mg/ml (red). (F) The anti-PD-1 antibody had no effect on cell survival in microspheres in normoxia (clear
bars) and 1% hypoxia (filled bars). Cytotoxity is determined by measuring LDH release at day 14 and normalized by the control. ****p<0.0001.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Small chemical inhibition of PD-1/PD-L1 interaction in 1% hypoxia measured at day 14 shows a dose-dependent increase in Mtb
growth with PD-1 inhibition.
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microspheres (Figure 5F). This confirms that an excess of TNF-a is the primary driver of increased
Mtb growth caused by PD-1 inhibition in the 3D model.
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Figure 4. PD-1 inhibition increases secretion of multiple cytokines and growth factors. PD-1/PD-L1 signalling was inhibited by Spartalizumab, a
humanized IgG4 anti-PD1 monoclonal antibody, in Mtb-infected microspheres at 20 and 200m/ml in normoxia. Supernatants were collected at day 14
and accumulation of cytokines and growth factors was analysed by Luminex 35-multiplex assay. Concentrations were normalized to secretion by Mtb
infected microspheres to demonstrate relative fold change, and individual concentrations are shown in Figure 4—figure supplement 1. The
experiment was performed twice with three replicates. Red font: **p<0.001 for Spartalizumab versus isotype control.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Cytokine accumulation around microspheres after inhibition of PD-1/PD-L1 signalling with Spartalizumab, a humanized IgG4
anti-PD1 monoclonal antibody at 20 and 200 mg/ml in normoxia (N) and 1% hypoxia (H).
Figure supplement 2. PD-1 inhibition increases secretion of multiple cytokines and growth factors in 1% hypoxia.
Figure supplement 3. Spartalizumab induces TNF-a secretion in uninfected and infected microspheres, which is neutralised by anti-TNF-a.
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TNF-a is highly expressed in TB granulomas and sputum TNF-a
negatively correlates with circulating PD-1 expression
Finally, to establish the in vivo relevance of our cell culture model findings, we performed immuno-
histochemical analysis of biopsies from patients with standard TB and anti-PD-1 associated TB. TNF-
a was expressed within TB granulomas, with greater immunoreactivity than control lung tissue at the
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Figure 5. Addition of TNF-a increases Mtb growth in microspheres in normoxia. Recombinant human G-CSF, GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-a, IL-
1RA, MIP-1a, MIP-1b or RANTES were added either individually (A and B) or in combination pools (C) to Mtb-infected microspheres at ‘low’
concentrations, defined as that measured in media around spheres after anti-PD-1 treatment. Recombinant human TNF-a increases growth of Mtb,
whilst other pro-inflammatory cytokines did not (A). GM-CSF has a lesser growth-promoting effect (B). The only combination pool that increased Mtb
growth was the pro-inflammatory cytokine pool, containing TNF-a (C). (D) TNF-a results in a dose-dependent increase in the Mtb growth over time. (E)
Anti-TNF-a neutralising antibodies partially suppress the increased Mtb growth caused by TNF-a augmentation. Anti-TNF-a from Thermo Fisher
Scientific. (F) Anti-PD1 antibody incorporation within microspheres increases of Mtb growth at day 7, and this effect is reversed by concurrent anti-TNF-
a neutralising antibodies within microspheres. The constituent of the cytokine pools are: Growth factor pool (GF: GM-CSF and G-CSF), Anti-
Inflammatory cytokine pool (Anti-Inf: IL-10 and IL-1RA), Pro-Inflammatory cytokine pool (Pro-Inf: TNF-a, IL-6 and IL-12) and Chemokine pool (Chemo:
RANTES, MIP-1a, MIP-1b).
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Individual Mtb growth curves at ‘high’ cytokine concentration, five times the concentration measured in media after anti-PD-1
treatment.
Figure supplement 2. Anti-TNF-a neutralizing antibodies supress the Mtb growth following TNF-a from a different source (Anti-TNF-a from Sigma-
Aldrich, UK).
Figure supplement 3. TNF-a skews polarization of monocytes to macrophages with lower CD80 expression.
Figure supplement 4. Hierarchical gating strategy used to identify lymphocyte and monocytic populations from decapsulated microspheres containing
human peripheral blood monocular cells.
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excision margin of lung cancer (Figure 6A). Consistent with our cell culture observations, TNF-a
immunostaining was extensive in a biopsy from a patient that developed pulmonary TB whilst
treated with pembrolizumab, an anti-PD-1 antibody (Figure 6B). Quantitative analysis of differences
between standard TB and anti-PD-1 TB was not possible due to the unique nature of this clinical
specimen, as TB diagnosis is usually made by bronchoalveolar lavage as opposed to percutaneous
biopsy.
We then analysed the association between PD-1 expression by circulating CD4+ and CD8+ T cells
and sputum TNF-a concentrations in a previously reported cohort (Walker et al., 2017). Although
this involved comparing PD-1 expression by circulating T cells, remote from the site of disease, with
total TNF-a concentration in the sputum, we hypothesised that a reverse association would support
the conclusion that PD-1 limits TNF-a secretion in patients. Consistent with this, CD4+ T cell PD-1
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Figure 6. TNF-a is expressed in human TB granulomas and sputum TNF-a concentrations negatively correlate with circulating PD-1 expression. (A)
TNF-a is expressed within human lung TB granulomas, with greater immunoreactivity than control lung tissue at the excision margin of lung cancer (i
and ii). Quantification of TNF-a immunostaining (n = 5) in TB cases was significantly higher than controls (n = 5) (iii). (B) TNF-a immunostaining was
extensive in the lung granuloma of a patient that developed TB whilst treated with pembrolizumab, a humanized anti-PD-1 antibody (n = 1). (C) CD4+ T
cell PD-1 expression on circulating PBMC negatively correlates with sputum TNF-a concentration in a separate cohort where paired sputum and PBMCs
samples are available. Green dots, healthy controls; Black TB cases; Orange respiratory symptomatics. Analysis by Spearman’s correlation analysis gave
r-value of  0.341 with p=0.0484.
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expression negatively correlated with sputum TNF-a, with a significant negative association despite
the relatively low sample numbers, which would be expected to obscure an effect (Figure 6C).
Discussion
Although Mtb kills more people than any other infection worldwide, an enduring enigma is that 90%
of those exposed exert lifelong control of the pathogen. In seminal post-mortem studies when TB
was highly prevalent in the United States, Opie showed that 30% of humans who died from other
causes had viable Mtb present in the lung apices (Opie and Aronson, 1927). Therefore, in the
majority of exposed individuals, a stable relationship forms between host immune cells and Mtb
without disease developing. Disseminated TB disease often develops in immunocompromised indi-
viduals, such as advanced HIV infection, newborn infants or following anti-TNF-a therapy, and this
observation informs the view that TB can arise as a disease of a deficient immune response to the
pathogen (O’Garra et al., 2013).
However, the commonest form of human TB, and the one that leads to transmission, is apical pul-
monary disease (Elkington et al., 2011). This occurs most frequently in young adults between the
ages of 20–25 with the strongest recall response to Mtb antigens, as measured by the Mantoux test
(Comstock et al., 1974). Therefore, these clinical observations demonstrate that infection results in
a stable symbiosis between host and pathogen in the majority of individuals, and a pronounced
immune response associates with the subsequent development of infectious pulmonary disease. The
recently emerging clinical phenomenon of TB rapidly developing after initiating anti-PD-1 immuno-
therapy (Fujita et al., 2016; Lee et al., 2016; Chu et al., 2017; Picchi et al., 2018; Jensen et al.,
2018; Elkington et al., 2018; He et al., 2018; Takata et al., 2019; Barber et al., 2019; Tsai et al.,
2019; van Eeden et al., 2019) further reinforces that an excessive immune response in TB can be
harmful.
PD-1 is expressed on T cells at the site of TB disease and PD-1 expression on circulating CD4+ T
cells associates with bacterial load (Day et al., 1995). PD-1 expression is elevated in circulating CD4
T cells in TB (Shen et al., 2016) and has been proposed to limit an effective host immune response.
Consequently PD-1 inhibition has been advanced as a therapeutic target to accelerate clearance of
infection (Zumla et al., 2016; Shen et al., 2016; Jurado et al., 2008; Singh et al., 2013;
Suarez et al., 2019; Jiang et al., 2014). However, from an evolutionary perspective, PD-1 is pro-
posed to limit immunopathology in the face of chronic antigenic stimulation (Sharpe and Pauken,
2018). Therefore, it is equally plausible, and indeed perhaps more logical, that PD-1/PD-L1 pathway
up-regulation in TB is a physiologically appropriate response to the persistent pathogen. We found
that hypoxia further up-regulated the PD-1/PD-L1/2 axis, consistent with hypoxia increasing expres-
sion in cancer (Noman et al., 2014), and TB lesions are hypoxic both in model animals and human
lesions (Belton et al., 2016; Via et al., 2008). Analysis of the effect of hypoxia is complicated that
both host and pathogen physiology are altered, with hypoxia causing reduced Mtb growth
(Devasundaram et al., 2016; Ortega et al., 2014; Eoh and Rhee, 2013) but also causing diverse
host physiological changes. PD-1 may be particularly important in limiting excessive inflammation
and pathology in conditions of low oxygen tension. TB reactivation following immune checkpoint
blockade, and the extreme susceptibility of PD-1 deficient mice to Mtb infection (La´za´r-
Molna´r et al., 2010; Barber et al., 2011), would support such a regulatory role, even though it runs
counter to widely advanced disease paradigms.
Our work further highlights the double-edged sword of the host immune response in TB
(Ehlers, 1999). TNF-a is clearly essential to an effective host immune response to TB, as disease fre-
quently develops after treatment with anti-TNF-a antibodies (Keane et al., 2001), and TNF-a inhib-
its Mtb growth in zebrafish macrophages (Clay et al., 2008) and human alveolar macrophages
(Hirsch et al., 1994). However, excessive TNF-a is also associated with poor outcomes in TB. In
human cells, an excess of TNF-a can increase Mtb growth (Byrd, 1997; Engele et al., 2002), consis-
tent with our observations. In patients with active TB, TNF-a expression by Mtb-specific T cells is
increased (Harari et al., 2011; Tebruegge et al., 2015) and TNF-a associates with more severe
radiological findings (Casarini et al., 1999; Tsao et al., 2000). In diverse model systems, excessive
TNF-a has been shown to cause harmful inflammation (Bekker et al., 2000; Taylor et al., 2005;
Tsenova et al., 1999; Roca and Ramakrishnan, 2013; Tzelepis et al., 2018), consistent with TNF-a
exerting a bell-shaped effect on host immunity, with either deficit or excess detrimental. Similarly,
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we report a deleterious effect of additional GM-CSF, in contrast to GM-CSF improving control of
Mtb growth in murine macrophages (Rothchild et al., 2014). This suggests that cytokine responses
are highly dose and context dependent, potentially with each demonstrating non-linear responses
leading to a complex matrix of what may denote the optimal cytokine profile for Mtb control. Con-
sistent with our findings, in the one patient that developed TB on anti-PD-1 treatment where longitu-
dinal samples are available, there was a spike in PPD-specific TNF-a expressing cells prior to with
the development of active TB (Barber et al., 2019), consistent with PD-1 acting as a regulator of
TNF-a expression in TB. Taken together, these findings demonstrate a harmful effect of excessive
TNF-a in TB.
We found that multiple cytokines and chemokines were increased after PD-1 inhibition, and
therefore events in humans are likely to be more complex than TNF-a excess alone. The augmented
inflammation may have multiple harmful effects, such as recruitment of excessive inflammatory cells
and destruction of the extracellular matrix (Cambier et al., 2017; Al Shammari et al., 2015;
Mishra et al., 2017), which favour Mtb growth. In the mouse model of TB, one key role of PD-1 is to
limit IFN-g production (Sakai et al., 2016), and we have shown that excess IFN-g also accelerates
Mtb growth in microspheres (Tezera et al., 2017a). We did not show an effect of TNF-a on cell sur-
vival, although TNF-a has been reported to increase macrophage necrosis in the zebrafish model,
via a mitochondrial-lysosomal-endoplasmic reticulum circuit (Roca and Ramakrishnan, 2013;
Roca et al., 2019). The effect of PD-1 inhibition on macrophage polarisation and survival warrants
further investigation, as this is likely to be one determinant of outcome (Lerner et al., 2017;
Cronan et al., 2016).
As in all in vitro systems, the bioelectrospray model has limitations (Elkington et al., 2019). For
example, it does not permit the ingress of new inflammatory cells, and therefore can only be used to
investigate the early events resulting from anti-PD-1 treatment, and not the recruitment of inflamma-
tory cells by increased chemokine secretion. In addition, although it permits longer analysis of the
host-pathogen interaction than other human primary cell culture systems, the 3 week standard
experiment remains shorter than human infection, and so it models early events. We have not yet
characterised which cells produce TNF-a, nor the wider phenotypic changes that result from inhibi-
tion of the PD-1 axis. The optimal approach would be to integrate single cell RNAseq to the analysis
pipeline, so the phenotype of different cells can be comprehensively analysed. As microspheres can
be readily dissolved by incubation in EDTA to release the cells, the system is suited for this technical
development.
The common side effects of anti-PD-1 treatment in patients are termed immune related Adverse
Events (irAEs), which are autoimmune in nature (Postow et al., 2018). We have proposed that an
autoimmune process may exacerbate pathology in TB (Elkington et al., 2016), and others have sug-
gested that a loss of tolerance underlies progression to active TB (Divangahi et al., 2018; Olive and
Sassetti, 2018). The common theme is that an excessive response to antigens, whether host or
pathogen-derived, can drive disease in TB and our findings further support this conclusion. PD-1
may act to fine tune the balance between pro- and anti-inflammatory responses necessary to control
infection without causing pathology. Notably, immune related adverse events to immune checkpoint
inhibitors may be treated with anti-TNF-a antibodies (Postow et al., 2018), suggesting TNF-a may
be the primary driver of both autoimmunity and TB pathology after PD-1 treatment.
Our model provides the mechanistic insights into a clinical phenomenon with significant implica-
tions for future TB treatment and vaccine approaches. Simply driving a stronger immune response to
Mtb seems unlikely to be beneficial, as clinical and epidemiological data suggest it may be harmful.
For example, host-directed therapies may be designed to accelerate bacterial clearance whilst con-
currently reducing immunopathological effects by appropriate skewing of macrophage phenotype.
A more nuanced view considering the different immunological phases of TB is essential, differentiat-
ing events at the point of initial exposure from the late events at the apex of the lung, where exces-
sive inflammation leads to immunopathology and transmission (Elkington and Friedland, 2015).
Defining the distinction between a protective and pathological immune response in human TB
remains a key unanswered question, essential to inform new interventions to control the TB
pandemic.
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Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Strain, strain
background
(Mycobacterium
tuberculosis)
H37Rv (From Ref: 20) Used at multiple
of infection of 0.1
Strain, strain
background
(Mycobacterium
tuberculosis)
H37Rv pMV306hsp+
LuxAB+G13+CDE
(From Ref: 20) Used at multiple
of infection of 0.1
Strain, strain
background
(Mycobacterium
tuberculosis)
H37Rv pMV306hsp
encoding the
wild-type FFluc
(From Ref: 20) Used at multiple
of infection of 0.1
Biological sample
(Antibodies)
Antibody anti-CD45-V500 Horizon
(Clone no. HI30)
BD Biosciences Cat.No.563792 Monoclonal
mouse antibody
Antibody anti-CD3 Brilliant Violet 785
(Clone no. OKT3)
Biolegend Cat.No.317330 Monoclonal
mouse antibody
Antibody anti-CD3-PE
(Clone no. HIT3a)
Biolegend Cat.No.300308 Monoclonal
mouse antibody
Antibody anti-CD4 Brilliant Ultra
Violet 496 (Clone no. SK3)
BD Bioscience Cat.No.612937 Monoclonal
mouse antibody
Antibody anti-CD4-PerCP
(Clone no. OKT4)
Biolegend Cat.No.317432 Monoclonal
mouse antibody
Antibody anti-CD8 Brilliant
Violet 605
(Clone no. RPA-T8)
Biolegend Cat.No.301040 Monoclonal
mouse antibody
Antibody anti-CD8-APC
(Clone no. SK1)
Biolegend Cat.No.344722 Monoclonal
mouse antibody
Antibody anti-CD103-APC
(Clone no. Ber-ACT8)
BD Biosciences Cat.No.563883 Monoclonal
mouse antibody
Antibody anti-CD69 Brilliant
Ultra Violet 395
(Clone no. FN50)
Biolegend Cat.No.310902 Monoclonal
mouse antibody
Antibody anti-HLA-DR-PerCP
(Clone no. L243)
Biolegend Cat.No.307628 Monoclonal
mouse antibody
Antibody anti-CD279-BB515
(Clone no. EH12.1)
BD Biosciences Cat.No.564494 Monoclonal
mouse antibody
Antibody anti- CD-274-BB515
(Clone no. MIH1)
BD Biosciences Cat.No.564554 Monoclonal
mouse antibody
Antibody anti-PD-1 Brilliant
Violet 421
(Clone no.EH12.1)
BD Biosciences Cat.No.562516 Monoclonal
mouse antibody
Antibody anti-CD11b-APC
(Clone no. ICRF44)
Biolegend Cat.No.301310 Monoclonal
mouse antibody
Antibody anti-CD45-APC/Cy7
(Clone no. 2D1)
Biolegend Cat.No.368516 Monoclonal
mouse antibody
Antibody anti-CD14-AP/APC
(Clone no. HCD14)
Biolegend Cat.No.325608 Monoclonal
mouse antibody
Antibody anti-True-Stain
Monocyte Blocker
Biolegend Cat.No.426102 Monoclonal
mouse antibody
Antibody anti-CD4
(Clone no. M7310)
DAKO Cat.No.M7310 Monoclonal
mouse antibody
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Antibody anti-CD8
(Clone no. M7103)
DAKO Cat.No. M7103 Monoclonal
mouse antibody
Antibody anti-PD1
(Clone no. ab5287)
Abcam Cat.No.ab52587 Monoclonal
mouse antibody
Antibody anti-TNF-a
(Clone no. ab1793)
Abcam Cat.No.ab1793 Monoclonal
mouse antibody
Antibody Spartalizumab Selleckchem Cat.No.A2017 20 mg/ml and 200 mg/ml,
monoclonal, mouse IgG4
Antibody IgG4 Sino Biologicals Cat.No.13505-HNAH 20 mg/ml and 200 mg/ml,
monoclonal, mouse IgG4
Antibody Mouse IgG1 kappa
Isotype Control
(P3.6.2.8.1),
Thermo
Fisher Scientific
Cat.No.16-4714-82 50 mg/ml, mouse
monoclonal IgG2A
Antibody Mouse IgG1 Negative
Control, clone Ci4
Merck
Life Sciences
Cat.No.MABC002 51 mg/ml, mouse
monoclonal IgG2A
Antibody anti-TNF-a Thermo
Fisher Scientific
Cat.No.16-7348-81 52 mg/ml, mouse
monoclonal IgG2A
Sequence-based reagent
(Applied Biosystems TaqMan
Gene Expression primers)
GAPDH Thermo
Fisher Scientific
#Hs02758991_g1
b2-Microbulin Thermo Fisher
Scientific
#Hs00608023_m1
FNTA Thermo Fisher
Scientific
#Hs00357739_m1
PDCD1 Thermo Fisher
Scientific
#Hs01550088_m1
CD274 Thermo Fisher
Scientific
#Hs00204257_m1
PDCD1LG2 Thermo Fisher
Scientific
#Hs00228839_m1
HIF-1a Thermo Fisher
Scientific
#Hs00153153_m1
Commercial
assay or kit
CytoTox-Glo
Cytotoxicity Assay
Promega G9291 Commercial
assay or kit
Lactate Dehydrogenase
Activity Assay Kit
Merck 11 644 793 001 Commercial
assay or kit
Cytokine and Chemokine
35-Plex Human
ProcartaPlex Panel
Thermo Fisher
Scientific
LHC6005M Commercial
assay or kit
Chemical
compound, drug
PD-1/PD-L1 Inhibitor 1 Cambridge
Biosciences, UK
#1675201-83-8 Chemical
compound
Recombinant
Human G-CSF
ImmunoTools Cat.No.11343115 1 ng/ml and 5 ng/ml
Recombinant
Human GM-CSF
ImmunoTools Cat.No.11343125 0.25 ng/ml and 1.25 ng/ml
Recombinant
Human IL-1RA/IL1 F3
ImmunoTools Cat.No.11344876 1.25 ng/ml and 6.25 ng/ml
Recombinant
Human IL-10
ImmunoTools Cat.No.11340105 0.2 ng/ml and 1 ng/ml
Recombinant
Human IL-6
ImmunoTools Cat.No.11340066 10.0 ng/ml and 50.0 ng/ml
Recombinant
Human IL-12
ImmunoTools Cat.No.11349125 0.5 ng/ml and 2.5 ng/ml
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Recombinant
Human TNF-a
ImmunoTools Cat.No.11343017 0.3 ng/ml, 1.5 ng/ml,
7.5 ng/ml and 15 ng/ml
Recombinant
Human IL-15
ImmunoTools Cat.No.11340155 0.5 ng/ml, 5 ng/ml
and 50 ng/ml
Recombinant
Human IL-17A
ImmunoTools Cat.No.11340176 1 ng/ml, 10 ng/ml
and 100 ng/ml
Recombinant
Human IL-17F
ImmunoTools Cat.No.11349176 1 ng/ml, 10 ng/ml
and 100 ng/ml
Recombinant
Human RANTES
ImmunoTools Cat.No.11343196 0.3 ng/ml and 1.5 ng/ml
Recombinant
Human MIP-1a
ImmunoTools Cat.No.11343206 1.5 ng/ml and 7.5 ng/ml
Recombinant
Human MIP-1b
ImmunoTools Cat.No.11343223 1.0 ng/ml
and 5 ng/ml
Recombinant
Human MCP
ImmunoTools Cat.No.11343386 1 ng/ml, 10 ng/ml
and 100 ng/ml
Software,
algorithm
FlowJo BD Bioscences version 10.6.1 Software
BD FACSDiva
Software
BD Biosciences Software
Graphpad Prism GraphPad
Software LLC
v7.05 Software
M. tuberculosis culture
M. tuberculosis H37Rv (Mtb) was cultured in Middlebrook 7H9 medium (supplemented with 10%
ADC, 0.2% glycerol and 0.02% Tween 80) (BD Biosciences, Oxford). Bioluminescent Mtb containing
luxABCDE (Mtb lux+) and Mtb expressing ffLuc (Mtb ffLuc+) were cultured with kanamycin 25 mg/
ml. Luminescence was measured with either GloMax 20/20 single tube luminometer (Promega,UK)
or GloMax Discover microplate reader (Promega,UK). Cultures at 1  108 CFU/ml Mtb (OD = 0.6)
were used for all experiments at multiplicity of infection (MOI) of 0.1. Live Mtb was used in all experi-
ments apart from the time lapse microscopy, which used UV killed TB. Mtb colony counting was per-
formed by serial dilution on Middlebrook 7H11 Agar. Bioluminescence from the Mtb ffLuc+ was
induced using D-luciferin (ThermoFisher, UK) at a concentration of 750 mM in Hank’s balanced salt
solution (HBSS).
PBMC cell isolation from human blood
For the 3D microsphere experiments, PBMC were separated from single donor leukocyte cones
(National Health Service Blood and Transfusion, Southampton, UK) by density gradient centrifuga-
tion over Ficoll-Paque (GE Healthcare Life Sciences). Ethical approval for these studies was provided
by the National Research Ethics Service Committee South Central - Southampton A, ref 13/SC/0043.
Study participants for the correlation analysis of sputum-TNF-a with PD-1 expression on CD4+
and CD8+ T cells are the cross-sectional study individuals in a previously reported cohort
(Walker et al., 2017; Walker et al., 2019). Participants were recruited from an outpatient clinic in
Khayelitsha, South Africa and were either healthy volunteers, non-TB respiratory symptomatics or
recently diagnosed TB patients. Flow cytometric analysis was performed on cryopreserved PBMC
isolated from whole blood as previously reported (Walker et al., 2019). The study was approved by
the University of Cape Town Human Research Ethics Committee (REF 516/2011) and conducted in
accordance with the Declaration of Helsinki.
Analysis of PD-1 expression in blood and lung of TB patients
Lung tissue and matched PBMC were obtained from the AHRI Lung study cohort approved by the
Biomedical Research Ethics Committee (BREC) of the University of Kwa-Zulu Natal, BREC reference:
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BE019/13. All participants underwent surgical resection to treat TB related lung complications,
including haemoptysis, bronchiectasis, persistent cavitatory disease, shrunken or collapsed lung or
drug-resistant infection, at the King Dinuzulu Hospital in Durban, KwaZulu- Natal and Inkosi Albert
Luthuli Central Hospital (IALCH) in Durban, KwaZulu-Natal. PBMC were isolated from whole blood
using standard Ficoll-Histopaque (Sigma) density gradient centrifugation by standard protocol.
Lung tissues was cut into approximately 1 mm3 pieces, washed several times with cold HBSS
(Lonza) and re-suspended in 8mls of pre-warmed digestion media R10 (RPMI supplemented with
10% FCS, 2 mM L-glutamate, 100 U/ml Penstrep), containing 0.5 mg/ml collagenase D (Roche) and
40 U/ml DNaseI (Roche), and transferred to GentleMACS C-tubes (Miltenyi) for mechanical digestion
according to the manufacturer’s instructions. The suspension was incubated for 30 min at 37˚C, fol-
lowed by an additional mechanical digestion step and another 30 min incubation step at 37˚C. The
final suspension was passed through a 70 mm cell strainer and washed twice in HBSS. PBMC and
lung cells were phenotyped by surface staining with a near-infrared live/dead cell viability cell stain-
ing kit (Invitrogen) and a cocktail of fluorochrome conjugated antibodies: aCD45-V500 Horizon clone
HI30 (BD Biosciences), aCD3 Brilliant Violet 785 clone OKT3 (Biolegend), aCD4 Brilliant Ultra Violet
496 clone SK3 (BD Bioscience), aCD8 Brilliant Violet 605 clone RPA-T8 (Biolegend), aCD103-APC
clone Ber-ACT8 (BD Biosciences), aCD69 Brilliant Ultra Violet 395 clone FN50 (Brilliant Horizon),
aPD-1 Brilliant Violet 421 clone EH12.1 (BD Biosciences). Cells were stained with 25 uL of antibody
cocktail in the dark for 20 min at room temperature followed by washing with PBS, then fixed in 2%
PFA. Data was acquired using BD Aria Fusion cytometer and analyzed using FlowJo Software v.9.9
(Treestar Inc, Ashland, OR).
Immunohistochemistry of paraffin-fixed tissue
Immunohistochemical analysis was performed on paraffin-embedded lung tissue from patients with
pulmonary TB and lung cancer that were mounted at 4 mm thin onto APS coated glass slides and
dried, using the following antibodies: anti-CD4 (Clone no. M7310) (DAKO), anti-CD8 (Clone no.
M7103) (DAKO), anti-PD1 (Clone no. ab5287) (Abcam) and anti-TNF-a (Clone no. ab1793) (Abcam).
Staining was done at optimised concentrations usingrecommended buffers for each antibody.
Microencapsulation of cells
Microspheres were generated with an electrostatic generator (Nisco, Zurich, Switzerland) as
described previously (Tezera et al., 2017b). Briefly, PBMC were infected overnight with Mtb in a
250 cm2 flask, cells were detached, pelleted and mixed with 1.5% sterile alginate (Pronova UP MVG
alginate, Nova Matrix, Norway) and 1 mg/mL collagen (Advanced BioMatrix, USA) at a final concen-
tration of 5  106 cells/ml. The cell-alginate suspension was injected into the bead generator where
microspheres were formed in an ionotropic gelling bath of 100 mM CaCl2 in HBSS. After washing
twice with HBSS with Ca2+/Mg2+, microspheres were transferred in RPMI 1640 medium containing
10% human AB serum and incubated at 37˚C. Microspheres were either dispensed into eppendorfs,
which were then randomly allocated to different environmental conditions, or plated into a 96-well
plate with conditions in triplicate according to a pre-determined template. For experiments in hyp-
oxia, microspheres were incubated in 1% oxygen in Galaxy 48 R CO2 incubator (Eppendorf, UK) until
analysis. Supernatants were collected at defined time points. Time points described are days post
infection.
Live cell imaging
Uninfected or UV killed Mtb infected cells suspended in alginate-collagen matrix were plated in an
eight well m-Slide (ibidi GmbH, Germany). HBSS containing Ca2+ was used for cross-linking of algi-
nate in the extracellular matrix for 15 min and then replaced with RPMI medium with 10% human AB
serum. Samples were imaged using an Olympus IX81 time-lapse microscope with temperature of 37˚
C and CO2 concentration 5%. Z-stacks 200 mm in height were captured at one position in each sam-
ple every 30 min for 48 hr. Images were exported as tif files and opened in ImageJ.
PD-1/PD-L1 Inhibition
Small chemical inhibition of PD-1/PD-L1 signalling was by PD-1/PD-L1 Inhibitor 1 (CAS Registry
#1675201-83-8, Cambridge Biosciences, UK), a compound that competitively blocks the interaction
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of PD-1 with it ligand protein PD-L1 (Guzik et al., 2017). Inhibitor one was prepared in DMSO
(Sigma-Aldrich,UK) at a concentration of 6.3 mM and dissolved to a concentration of 1 nM, 10 nM,
100 nM and 1 mM in complete media and added to media around microspheres on the day after
encapsulation. Luminescence was monitored on specific days. For the microspheres incubated in
hypoxic conditions, measurement of luminescence was repeated for every 30 min after the addition
of luciferin until the reading plateaued, which was usually 2 hr.
In antibody inhibitory experiments, spartalizumab (Selleckchem, Germany), a humanised IgG4
anti-PD1 monoclonal antibody, was used to inhibit of PD-1/PD-L1 signalling in microspheres. Briefly,
cells were infected with Mtb overnight, pelleted and then a suspension of anti-PD1 antibodies (20
and 200 mg/ml) were added and pre-incubated for 1 hr. Cells were then encapsulated within micro-
spheres and kept for 14 days in either normoxia or 1% oxygen at 37˚C and 5% CO2. Mtb growth
was measured using luminescence and supernatants were taken for either cytokine or LDH measure-
ment. An IgG4 human antibody was used at the same concentration as a control.
Cell toxicity assays
Lactate dehydrogenase (LDH) release in the supernatants collected at different time points was ana-
lysed by a colorimetric activity assay as per manufacturer’s instructions (Roche, Burgess Hill, United
Kingdom). As a second assay, CytoTox-Glo Cytotoxicity Assay (Promega) was used, which measures
dead-cell protease activity released from cells without membrane integrity using a luminogenic pep-
tide substrate, the AAF-Glo Substrate. Luminescence from 96-well plates was analysed by GloMax
Discover (Promega). The LDH assay was suited for later time points, as this could be performed on
microspheres in eppendorfs, while the CytoTox glow required analysis in 96 well plates and so was
best suited to analysis in the first week.
Gene expression analysis
All the reagents were sourced from ThermoFisher Scientific (Paisley, UK). In brief, microspheres were
decapsulated with 5 mM EDTA, cells were pelleted and immediately lysed using TRIzol Reagent.
RNA was transcribed using High Capacity cDNA Reverse Transcription kit. TaqMan Universal master
mix and primers specific for genes were GAPDH (#Hs02758991_g1), b2-Microbulin
(#Hs00608023_m1), FNTA (#Hs00357739_m1), PDCD1 (#Hs01550088_m1), CD274
(#Hs00204257_m1), PDCD1LG2 (#Hs00228839_m1) and HIF-1a (Hs00153153_m1) were used for
qPCR according to the manufacturer’s instructions and the comparative threshold (CT) method was
employed to analyse all qPCR data.
Immunophenotyping of cells from microspheres
Microspheres were decapsulated with 5 mM EDTA in HBSS with no Ca2+/Mg2+ at day seven after
encapsulation and 2 million cells prepared for staining in RPMI with 5% foetal bovine serum. To mea-
sure the expression of PD-1 in CD4+ and CD8+ T cells and PD-L1 expression in CD14+CD11b+ cells,
the following antibody panel was used: CD3-PE (clone HIT3a, Biolegend), HLA-DR-PerCP (clone
L243, Biolegend), CD4-PerCP (clone OKT4, Biolegend), CD8-APC (clone SK1, Biolegend), CD11b-
APC (clone ICRF44, Biolegend), CD45-APC/Cy7 (clone 2D1, Biolegend), CD14-AP/APC (clone
HCD14, Biolegend), CD279-BB515 (Clone EH12.1, BD), CD-274-BB515 (Clone MIH1, BD) and True-
Stain Monocyte Blocker (Biolegend, USA). Gates were defined using fluorescence minus one control
after exclusion of the dead cells using Live/Dead fixable stain (ThermoFisher, UK). Gating strategy is
provided in Figure 5—figure supplement 4. Cells were acquired after fixing them in 2% paraformal-
dehyde in HBSS for 1 hr using FACSAria (Becton Dickinson, UK) and analysed by FACSDiva software
(Becton Dickinson) and Flow Jo version 10 (Treestar).
Cytokine supplementation
Microspheres were incubated in RPMI 1640 with 10% AB serum in an opaque 12-well tissue culture
plate with G-CSF, GM-CSF, IL-1RA, IL-6, IL-10, IL-12, IL-15, IL-17A, IL-17F, TNF-a, RANTES, MIP-1a,
MIP-1b and MCP at two concentrations determined by the cellular experiments, at 37˚C and 5%
CO2. All the cytokines were purchased from ImmunoTools (Germany), suspended in RPMI with 0.1%
human serum and kept at  80˚C until use. Bacterial growth was monitored with luminescence using
GloMax Discover microplate reader (Promega,UK).
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Luminex analysis
Samples were sterilised by filtration through a 0.22 mM Durapore membrane (MerkMillipore). Con-
centrations of cytokines (ThermoFisher, UK) were determined using a Bioplex 200 platform (Bio-Rad,
UK) according to the manufacturer’s protocol and quantified per milligram of total protein measured
by Bradford assay (Biorad).
Statistical analysis
All experiments were performed on a minimum of 2 occasions from separate donors as biological
replicates and on each occasion with a minimum of 3 technical replicates. Some donor-to-donor vari-
ation occurred in terms of absolute RLU, as expected in the analysis of primary human cells, but the
direction of effects were always consistent. Data presented are from a representative donor and
include the mean and SEM. Analysis was performed in Graphpad Prism v7.05. Students t-test was
used to compare pairs and ANOVA with Tukey’s correction for multiple comparisons for groups of 3
or more groups where it was appropriate. For the flow cytometric analysis of clinical samples, data
were analysed using Mann-Whitney test for comparing pairs and Kruskal-Wallis test with Dunn’s mul-
tiple comparisons test for three or more group.
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